UMIN試験ID | UMIN000039111 |
---|---|
受付番号 | R000044607 |
科学的試験名 | |
一般公開日(本登録希望日) | 2020/01/10 |
最終更新日 | 2020/01/10 02:26:26 |
日本語
英語
Evaluating the relationship between industry sponsorship and conflicts of interest among systematic review authors on pharmacological therapies for alcohol use disorder and the nature of results and conclusions of these reviews
日本語
英語
AUD-FCOI
日本語
英語
Evaluating the relationship between industry sponsorship and conflicts of interest among systematic review authors on pharmacological therapies for alcohol use disorder and the nature of results and conclusions of these reviews
日本語
英語
AUD-FCOI
北米/North America |
日本語
英語
Alcohol Use Disorder
精神神経科学/Psychiatry | 成人/Adult |
悪性腫瘍以外/Others
いいえ/NO
日本語
英語
Objectives: Our primary objectives are (i) to characterize the nature and types of conflicts of interest (both disclosed and undisclosed) of systematic review authors and (ii) to determine whether the direction of meta-analytic pooled effect estimates, when provided, and narrative results and conclusions from systematic reviews may be influenced by having systematic review authors with conflicts of interest. Our secondary objectives will be to evaluate (i) whether an association exists between risk of bias and financial conflicts of interest of systematic review authors; and (ii) whether a relationship exists between sponsorship of systematic reviews and their reported results and conclusions.
有効性/Efficacy
日本語
英語
日本語
英語
Objectives: Our primary objectives are (i) to characterize the nature and types of conflicts of interest (both disclosed and undisclosed) of systematic review authors and (ii) to determine whether the direction of meta-analytic pooled effect estimates, when provided, and narrative results and conclusions from systematic reviews may be influenced by having systematic review authors with conflicts of interest. Our secondary objectives will be to evaluate whether an association exists between risk of bias and financial conflicts of interest of systematic review authors
日本語
英語
(ii) whether a relationship exists between sponsorship of systematic reviews and their reported results and conclusions.
その他・メタアナリシス等/Others,meta-analysis etc
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
18 | 歳/years-old | 以上/<= |
90 | 歳/years-old | 未満/> |
男女両方/Male and Female
日本語
英語
Eligibility Criteria: To be included in our study, the study design must be a systematic review and or meta-analysis. We will use the PRISMA P deNAfinition of a systematic review meta-analysis, which states that a systematic review is a systematic review is a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies. Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies. 1. Furthermore, studies will be included if they compare at least one pharmacologic therapy to another (or in combination) or if they compare a pharmacologic therapy to an nonpharmacologic therapy, such as verbal alcoholism therapy. We will include all pharmacologic therapies, regardless of whether they are indicated for treatment of AUD (acamprosate, naltrexone, and disulfiram) or whether they are used off label. We will include studies along the following stages of progression: (i) stabilization following excessive use of alcohol, (ii) relapse prevention, or (iii) recovery maintenance. Furthermore, to qualify for inclusion, systematic reviews must have been published between September of 2016 and December of 2019. Only systematic reviews published in English and reviews that synthesize studies of human or animal data will be included.
日本語
英語
Eligibility Criteria: To be included in our study, the study design must be a systematic review and or meta-analysis. We will use the PRISMA P deNAfinition of a systematic review meta-analysis, which states that a systematic review is a systematic review is a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies. Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies. 1. Furthermore, studies will be included if they compare at least one pharmacologic therapy to another (or in combination) or if they compare a pharmacologic therapy to an nonpharmacologic therapy, such as verbal alcoholism therapy. We will include all pharmacologic therapies, regardless of whether they are indicated for treatment of AUD (acamprosate, naltrexone, and disulfiram) or whether they are used off label. We will include studies along the following stages of progression: (i) stabilization following excessive use of alcohol, (ii) relapse prevention, or (iii) recovery maintenance. Furthermore, to qualify for inclusion, systematic reviews must have been published between September of 2016 and December of 2019. Only systematic reviews published in English and reviews that synthesize studies of human or animal data will be included.
40
日本語
名 | |
ミドルネーム | |
姓 |
英語
名 | Matt |
ミドルネーム | |
姓 | Vassar |
日本語
英語
Oklahoma State University Center for Health Sciences
日本語
英語
Department of Psychiatry and Behavioral Sciences
74107
日本語
英語
1111 W 17th St. Tulsa, OK 74107
9185821972
matt.vassar@okstate.edu
日本語
名 | |
ミドルネーム | |
姓 |
英語
名 | Matt |
ミドルネーム | |
姓 | Vassar |
日本語
英語
Oklahoma State University Center for Health Sciences
日本語
英語
Department of Psychiatry and Behavioral Sciences
74107
日本語
英語
1111 W 17th St. Tulsa, OK 74107
9185821972
matt.vassar@okstate.edu
日本語
その他
英語
Oklahoma State University Center for Health Sciences
日本語
日本語
日本語
英語
日本語
その他
英語
Oklahoma State University Center for Health Sciences
日本語
日本語
海外/Outside Japan
日本語
英語
日本語
英語
日本語
英語
日本語
英語
Oklahoma State University Center for Health Sciences
日本語
英語
1111 W 17th St. Tulsa, OK 74107
9185821972
matt.vassar@okstate.edu
いいえ/NO
日本語
英語
日本語
英語
2020 | 年 | 01 | 月 | 10 | 日 |
OSF.IO
未公表/Unpublished
50
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
試験終了/Completed
2020 | 年 | 01 | 月 | 09 | 日 |
2020 | 年 | 01 | 月 | 09 | 日 |
2020 | 年 | 01 | 月 | 09 | 日 |
2021 | 年 | 01 | 月 | 01 | 日 |
日本語
英語
Data Collection Process: Data extraction will be performed by the same investigators MC and MH who performed the initial screening. As before, they will be blinded to the other investigators decisions. After data extraction, both investigators will meet and resolve any discrepancies. JMA and MV will be available for third party adjudication on an as needed basis.
2020 | 年 | 01 | 月 | 10 | 日 |
2020 | 年 | 01 | 月 | 10 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000044607
英語
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044607
研究計画書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ仕様書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ | |
---|---|
登録日時 | ファイル名 |